Expanding the Patient Pool for Rilonacept
Year: 2025
Type: article
Study design: Case Report
Abstract: Recurrent pericarditis complicates 15%-30% of acute pericarditis cases despite initial anti-inflammatory treatment. The RHAPSODY trial (Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis) showed rilonacept, an interleukin-1 cytokine trap, to be an effective therapeutic option for patients with pericarditis recurrence. This case series demonstrates the utility and challenges of rilonacept use in the types of patients excluded from RHAPSODY.
Source: JACC Case Reports
Authors: Emma St. John, Jessica R. Carey, Tanya Wilcox, John Ryan, Satvik Ramakrishna, Anees Daud, Denise Diaz-Robles, Adam Smith, Kristin Cowan, Libo Wang
Institutions: University of Utah, University of Utah Health Care
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $850
OpenAlex ID: W4412011773